(Reuters) - French artificial heart maker Carmat expects to break-even in 2027, it said on Monday, as it gradually resumes implants and faces strong demand in Europe ahead of its commercial launch in the United States.
The Aeson implant maker, which targets a U.S. launch in 2026, plans to ramp-up its production to 100 hearts in 2023 and further accelerate to 500 in 2024 and 1,000 in 2027.
"Strong interest in, and demand for Aeson make us particularly confident about the development of our sales," Carmat's Chief Executive Officer Stephane Piat said in a statement.
Providing financial targets for the first time, Carmat said it expects to achieve sales of 10-13 million euros ($10.9-14.1 million) in 2023, following the resumption of commercial implants of Aeson in November.
The company, which raised an additional 31.1 million euros via a dilutive share issue last December to finance the ramp-up, had been forced to suspend implants at the end of 2021 following a quality issue affecting some of its prostheses.
Last September, it reported a half-year net loss of 26 million euros with no revenues. Its annual results are scheduled for February 23.
($1 = 0.9216 euros)
(Reporting by Dina Kartit. Editing by Sharon Singleton)
21 When a patient presents with these signs and symptoms, pharmacists can intervene and rule out excessive water intake and medications associated hyponatremia generic cialis vs cialisREPLY